Suppression of F-18 Fluorodeoxyglucose Uptake in Benign Uterine Leiomyomas With Danazol

Madhavi Tripathi, Madhur Kumar Srivastava, Gunjun Garg, Abhinav Jaimini, Namita Singh, Maria do Carmo Custódio de Souza, Prabhjot Kaur, Rajnish Sharma, Anupam Mandal
In: Clinical Nuclear Medicine · 2009 · vol. 34(7) , pp. 452–455 · doi:10.1097/rlu.0b013e3181a7d02a · PMID:19542955 · W2014266684
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

A 40-year premenopausal woman was referred by her treating oncologist for F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to rule out disease recurrence or metastasis. She had completed therapy for Hodgkin lymphoma (Stage IIA) 1 year earlier. Post-therapy gallium-67 study showed no evidence of residual disease and the patient was on regular follow-up. The only abnormality detected on the FDG-PET/CT study was a focus of abnormal FDG accumulation in the pelvis, suprapubically. Fused PET-CT localized the uptake to the uterine myometrium in the fundal region posteriorly corresponding to mild inhomogeneity in attenuation with a bulky uterus on CT. MRI of the pelvis confirmed the presence of a uterine leiomyoma in the fundal region. The patient was put on danazol (200 mg twice daily for 14 days) and a repeat PET-CT of the pelvis was done after 14 days, which revealed complete disappearance of FDG uptake in the leiomyoma. This proved that F-18 FDG uptake in the leiomyoma was probably related to its vascularity.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (8)

Source provenance

openalex
last seen: 2026-05-11T05:42:58.953575+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK